Page 25 - Priority Review News Today

The FDA has accepted for Priority Review the BLA for tarlatamab for adults with relapsed or refractory SCLC.

Sickle cell disease, a group of inherited blood disorders, affects around 100,000 individuals in the United States and is predominant among African Americans.

VANCOUVER, BC, Dec. 13, 2023 /PRNewswire/ - Numinus Wellness Inc.  , a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies,...

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Companys...

Biotech Seeks Approval of Synthetic Blood Vessel Graft

The U.S. Food and Drug Administration (FDA) approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older.

/PRNewswire/ -- Dizal presented compelling data from its robust portfolio of hematological oncology at the 65th American Society of Hematology (ASH) Annual...

The FDA has granted Priority Review to the sBLA for Keytruda plus Padcev for first-line treatment of locally advanced or metastatic urothelial cancer.

The FDA approved Vertex/CRISPR Therapeutics’ Casgevy® and Bluebird Bio’s Lyfgenia®, the first cell-based gene therapies to treat sickle cell disease…

Share on Twitter Print Share Back to top On December 8, 2023 the U.S. Food and Drug Administration (FDA) approved Casgevy and Lyfgenia, both cell-based gene therapies for the treatment...